Products for Research Use Only

BD-1008-d5 (dihydrobromide)

CAT: 0804-HY-100966S-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-100966S-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
BD-1008-d5 dihydrobromide is the deuterium labeled BD-1008 dihydrobromide. BD-1008 dihydrobromide is a nonselective σ receptor antagonist with Kis against σ1 receptor and σ2 receptor of 2 nM and 8 nM. The BD-1008 dihydrobromide has an extremely low affinity for the D2 receptor (Ki = 1112 nM) and dopamine transporter (DAT) (Ki > 10,000 nM). BD-1008 dihydrobromide significantly antagonizes dopamine release in the shell region of the nucleus accumbens via the σ₂ receptor. BD-1008 dihydrobromide blocks the self-administration behavior of σ agonists.BD-1008 dihydrobromide can be used for the study of addiction therapy that target the σ receptor[1][2][3].
UNSPSC
12352005
Target
Isotope-Labeled Compounds; Sigma Receptor
Type
Isotope-Labeled Compounds
Related Pathways
Neuronal Signaling; Others
Field of Research
Neurological Disease
Solubility
10 mM in DMSO
Smiles
[2H]C([2H])(N(C([2H])(CC1=CC(Cl)=C(Cl)C=C1)[2H])CCN2CCCC2)[2H].Br.Br
Molecular Formula
C15H19D5Br2Cl2N2
Molecular Weight
468.11
References & Citations
[1]Staelens L, et al. In vivo evaluation of [ (123) I]-3- (4-iodobenzyl) -1,2,3,4-tetrahydro-8-hydroxychromeno[3,4-c]pyridin-5-one: a presumed dopamine D4 receptor ligand for SPECT studies. Nucl Med Biol. 2005 Apr;32 (3) :293-9. |[2]Garcés-Ramírez L, et al. Sigma receptor agonists: receptor binding and effects on mesolimbic dopamine neurotransmission assessed by microdialysis. Biol Psychiatry. 2011 Feb 1;69 (3) :208-17.|[3]Hiranita T, et al. Stimulants as specific inducers of dopamine-independent σ agonist self-administration in rats. J Pharmacol Exp Ther. 2013 Oct;347 (1) :20-9.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported